scholarly journals Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy

AIDS ◽  
2010 ◽  
Vol 24 (11) ◽  
pp. 1765-1770 ◽  
Author(s):  
Chun Chao ◽  
Lanfang Xu ◽  
Donald Abrams ◽  
Wendy Leyden ◽  
Michael Horberg ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hiv Infection ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Combined Antiretroviral Therapy

scholarly journals Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana

2018 ◽  
pp. 1-11 ◽  
Author(s):  
Michael G. Milligan ◽  
Elizabeth Bigger ◽  
Jeremy S. Abramson ◽  
Aliyah R. Sohani ◽  
Musimar Zola ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Hodgkin Lymphoma ◽  
Cancer Care ◽  
The United States ◽  
Sociodemographic Factors ◽  
Hiv Status ◽  
Non Hodgkin Lymphoma ◽  
Combined Antiretroviral Therapy ◽  
Few Data ◽  
New Diagnosis

Purpose Botswana has a high prevalence of HIV infection. Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)—an AIDS-defining cancer—in the country. Patients and Methods This study used a prospective cancer registry to identify patients with a new diagnosis of NHL reporting for specialty cancer care at three hospitals in Botswana between October 2010 and August 2016. Treatment patterns and clinical outcomes were analyzed. Results One hundred four patients with a new diagnosis of NHL were enrolled in this study, 72% of whom had HIV infection. Compared with patients not infected with HIV, patients infected with HIV were younger (median age, 53.9 v 39.1 years; P = .001) and more likely to present with an aggressive subtype of NHL (65.5% v 84.0%; P = .008). All patients infected with HIV received combined antiretroviral therapy throughout the course of the study, and similar chemotherapeutic regimens were recommended for all patients, regardless of subtype or HIV status (six to eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). There was no difference in 1-year mortality among patients not infected with HIV and patients infected with HIV (unadjusted analysis, 52.9% v 37.1%; hazard ratio [HR], 0.73; P = .33; adjusted analysis, HR, 0.57; P = .14). However, when compared with a cohort of patients in the United States matched by subtype, stage, age, sex, and race, patients in Botswana fared worse (1-year mortality, 22.8% v 46.3%; HR, 1.89; P = .001). Conclusion Among patients with NHL reporting for specialty cancer care in Botswana, there is no association between HIV status and 1-year survival.

Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy

AIDS ◽  
2008 ◽  
Vol 22 (2) ◽  
pp. 301-306 ◽  
Author(s):  
Jerry Polesel ◽  
Gary M Clifford ◽  
Martin Rickenbach ◽  
Luigino Dal Maso ◽  
Manuel Battegay ◽  
...  
Keyword(s):  
Cohort Study ◽  
Antiretroviral Therapy ◽  
Hodgkin Lymphoma ◽  
Highly Active Antiretroviral Therapy ◽  
Non Hodgkin Lymphoma ◽  
Highly Active ◽  
Before And After

scholarly journals Hodgkin Lymphoma in People Living with HIV

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4366
Author(s):  
Jose-Tomas Navarro ◽  
José Moltó ◽  
Gustavo Tapia ◽  
Josep-Maria Ribera
Keyword(s):  
Hodgkin Lymphoma ◽  
Interdisciplinary Collaboration ◽  
Survival Rates ◽  
People Living With Hiv ◽  
Barr Virus ◽  
Non Hodgkin Lymphoma ◽  
Combined Antiretroviral Therapy ◽  
Epstein Barr ◽  
Living With Hiv ◽  
Hiv Negative

Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with cART. While the incidence of aggressive forms of non-Hodgkin lymphoma decreased after the advent of cART, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein–Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting. Currently, PLWH with HRL, including HL, are treated similarly to HIV-negative patients and, importantly, the prognosis of HL in PLWH is approaching that of the general population. In this regard, effective cART during chemotherapy is strongly recommended since it has been shown to improve survival rates in all lymphoma subtypes, including HL. As a consequence, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential drug–drug interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PLWH with HL. In this article the authors review and update the epidemiological, clinical and biological aspects of HL presenting in PLWH with special emphasis on advances in prognosis and the factors that have contributed to it.

HIV Infection

2017 ◽  
Author(s):  
Meena Kannan ◽  
Harrison Taylor ◽  
William Tyor
Keyword(s):  
Nervous System ◽  
Differential Diagnosis ◽  
Antiretroviral Therapy ◽  
Hiv Infection ◽  
Clinical Management ◽  
Cytomegalovirus Infection ◽  
Clinical Presentation ◽  
Opportunistic Infections ◽  
Cryptococcal Infection ◽  
Combined Antiretroviral Therapy

This chapter focuses on four common opportunistic infections of the nervous system associated with HIV infection, namely cryptococcal infection, cytomegalovirus infection, progressive multifocal leukoencephalitis, and toxoplasmosis. Essential features of neurobiology, clinical presentation, differential diagnosis, diagnostic workup, clinical management, and outcome are discussed for each condition. Although combined antiretroviral therapy for HIV has generally reduced the incidence of these complications of HIV infection, they remain important considerations, especially in areas in which antiretrovirals are unavailable or have limited availability.

Primitive Neuroectodermal Tumor in a Child with Human Immunodeficiency Virus Infection: A Rare Association

2019 ◽  
Author(s):  
Aman Gupta ◽  
Dharmagat Bhattarai ◽  
Bishnu Kumar Thapa ◽  
Mayur Parkhi ◽  
Pandiarajan Vignesh ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Virus Infection ◽  
Hiv Infection ◽  
Primitive Neuroectodermal Tumor ◽  
Neuroectodermal Tumor ◽  
Rare Association ◽  
Non Hodgkin Lymphoma ◽  
Wide Range ◽  
Immunodeficiency Virus

Abstract Children with human immunodeficiency virus (HIV) infection are reported to have various malignancies, most common being Non-Hodgkin lymphoma. Despite higher risk of malignancies, brain tumors are infrequently described in these children. We report Primitive Neuroectodermal tumor (PNET) in a young boy with HIV infection. PNET has never been described in association with HIV infection. Though a causative association cannot be established, it does emphasize that with longer survivals on effective antiretroviral therapy, we may see a wide range of malignancies more frequently.

Sign in / Sign up

Export Citation Format

Share Document